Arthritis News and Research RSS Feed - Arthritis News and Research Twitter

Many people start to feel pain and stiffness in their bodies over time. Sometimes their hands or knees or shoulders get sore and are hard to move and may become swollen. These people may have arthritis. Arthritis may be caused by inflammation of the tissue lining the joints. Some signs of inflammation include redness, heat, pain, and swelling. These problems are telling you that something is wrong. Joints are places where two bones meet, such as your elbow or knee. Over time, in some types of arthritis but not in all, the joints involved can become severely damaged. There are different types of arthritis. In some diseases in which arthritis occurs, other organs, such as your eyes, your chest, or your skin, can also be affected. Some people may worry that arthritis means they won’t be able to work or take care of their children and their family. Others think that you just have to accept things like arthritis.
Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. [More]
Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man. [More]
University of Oslo researchers find the cause of coeliac disease

University of Oslo researchers find the cause of coeliac disease

Professor Ludvig M. Sollid and his colleagues at the University of Oslo have found the cause of coeliac disease. To do so required really going into depth, right down to molecular level. [More]
R-Japan receives license for cell processing facility

R-Japan receives license for cell processing facility

R-Japan Co.,Ltd. obtained the license of cell processing facility under the Act on the Safety of Regenerative Medicine from the Ministry of Health, Labour and Welfare Kinki Bureau of Health and Welfare on June 29, 2015. [More]
Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms. [More]
Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study. [More]
ProfNet network experts available to discuss timely issues in your coverage area

ProfNet network experts available to discuss timely issues in your coverage area

Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. You can also submit a query to the hundreds of thousands of experts in our network – it's easy and free! [More]
Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline. [More]
New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions. [More]
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Malaria parasite protein essential for parasite invasion into red blood cells

Malaria parasite protein essential for parasite invasion into red blood cells

A new study led by researchers at Harvard T.H. Chan School of Public Health finds that a malaria parasite protein called calcineurin is essential for parasite invasion into red blood cells. Human calcineurin is already a proven target for drugs treating other illnesses including adult rheumatoid arthritis and lupus, and the new findings suggest that parasite calcineurin should be a focus for the development of new antimalarial drugs. [More]
University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

The Feinstein Institute for Medical Research and Molecular Medicine announced today that the fourth Anthony Cerami Award in Translational Medicine will be conferred to Thomas E. Starzl, MD, PhD, professor of surgery at the University of Pittsburgh School of Medicine. The award is in recognition of his research in organ transplantation and alloengraftment mechanisms. [More]
Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that its common shares will begin trading on the NASDAQ Global Select Market on June 29, 2015 under the symbol CXRX. [More]
Scripps Florida scientists receive $3.5 million to accelerate development of anti-diabetic compounds

Scripps Florida scientists receive $3.5 million to accelerate development of anti-diabetic compounds

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $3.5 million from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health to accelerate development of a new class of anti-diabetic compounds. [More]
Cytokine levels may help distinguish patients with suicidality

Cytokine levels may help distinguish patients with suicidality

One American dies from suicide every 12.8 minutes, making suicide the tenth leading cause of death in the United States according to the American Foundation for Suicide Prevention. [More]
PROMISSE study: Most women with lupus can expect good pregnancy outcomes

PROMISSE study: Most women with lupus can expect good pregnancy outcomes

One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors. [More]
3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006. [More]
Tackling fuel poverty can help reduce debilitating sickle cell disease, save significant money for NHS

Tackling fuel poverty can help reduce debilitating sickle cell disease, save significant money for NHS

Tackling fuel poverty in the homes of people with sickle cell disease could reduce debilitating attacks and save significant money for the NHS, according to a study by Sheffield Hallam University funded by the Chesshire Lehmann Fund. [More]
ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API). [More]
Advertisement
Advertisement